Hospitals consume vascular-access catheters, needle-free connectors and infusion sets the way offices consume paper — box by box, procedure by procedure. Four of the companies that supply them reported second-quarter results between 30 July and 6 August. The reports were not alike. One posted its fastest organic growth in three years; another lowered its revenue outlook for the year. All four stocks rose.

The push came from outside

The common cause was a hospital operator. HCA Healthcare's 24 July second-quarter report showed same-facility admissions up 2.5% even as inpatient elective cases fell 6% and the company raised its expected full-year drag from insurance-exchange coverage losses to $1.0–$1.2bn. The feared collapse in insured volumes after enhanced Affordable Care Act premium tax credits expired did not show up, and device stocks traded higher on the read-across. It landed inside a documented August rotation out of technology into healthcare, and days after KKR agreed to buy Integer Holdings for $5.7bn.

From 14 July to 14 August the four averaged +18.5%. Fourteen other medical-device makers in this database rose a median of roughly 18% over the identical window — Abbott +25.1%, Baxter +22.6%, Boston Scientific +21.6%, Stryker +9.0% — against 3.3% for the S&P 500 tracker. These four matched their industry. They did not lead it.

Only one business kept pace

Merit Medical, a Utah maker of disposable devices for cardiology, radiology and oncology procedures, is the exception. Revenue rose 9.7% to $418.8m, with organic constant-currency growth of 9% — its strongest in three years. Gross margin expanded 314 basis points to 51.4%, and operating income grew 29.5%, three times faster than sales. It raised full-year organic growth guidance to 6.9–7.5% and adjusted earnings to $4.25–$4.35 a share while absorbing $0.21 of tariff cost. Management said it has seen no slowdown in procedure volumes from the subsidy changes.

ICU Medical, which sells infusion-therapy consumables and Plum infusion pumps, is the improvement story rather than the growth story. Reported revenue barely moved, at $551.7m, but adjusted earnings of $2.37 a share beat the $1.91 consensus. Gross margin widened 470 basis points to 42.6%, and operating income reached $39.1m against $10.6m a year earlier. The revenue base is structurally smaller because it sold 60% of its IV Solutions business to Otsuka in 2025.

Becton Dickinson, the $50.5bn maker of syringes, IV catheters, pen needles and infusion pumps, grew 4.4% excluding currency. Margins went the other way: adjusted gross margin fell 100 basis points and adjusted operating margin 130, with about 110 basis points of tariff inside that. The company beat on earnings and raised guidance — the midpoint went from $12.62 to $12.67, a raise of 0.4%. Free cash flow of $1.7bn year-to-date is up 45%. A comparison headwind from its Alaris pump recall recovery costs 200 basis points of growth across fiscal 2027.

Teleflex, whose Arrow-brand vascular catheters and UroLift prostate system go into critical-care settings, diverges outright. It cut full-year constant-currency revenue growth guidance to 3.5–4.5% from 4.5–5.5%, with Interventional revenue down 1% and a BIOTRONIK integration pushed to year-end. Adjusted operating margin fell 520 basis points. Its earnings guide went up regardless — on buybacks, a $700m debt paydown and a lower tax rate.

Two pieces of the popular story about these companies are stale. Becton's Biosciences separation is finished: it closed on 9 February in a $17.5bn Reverse Morris Trust with Waters. And Teleflex abandoned its two-company split in December, agreeing instead to sell three businesses outright for $2.03bn. No break-up news landed in the month at all.

The month bought multiple, not earnings

Trailing earnings are unusable here — divestiture accounting leaves Becton at 55x, ICU Medical at 152x on near-zero reported profit, and Teleflex negative after a $905.6m loss last year. On forward earnings: Becton 14.5x, Merit 21.1x, Teleflex 20.6x, ICU Medical 22.4x. Three months ago, priced against the same consensus, ICU Medical stood at 15.1x, Merit at 14.5x and Becton at 11.5x. Becton rose 21.7% on a 0.4% guidance raise; Merit 27.8% on 5.4%; ICU Medical 19.2% on 8.6%. Only Teleflex got cheaper — and its price per dollar of gross profit is higher on forward numbers (4.94x) than trailing (4.34x), because the gross-profit base is shrinking faster than the price.

Participation is thinner than the average suggests. Remove each name's two best sessions and the group's month falls from 18.5% to 7.3%. Becton holds at 11.2% and Merit at 16.7%; ICU Medical drops to 2.1%, because 7 August alone was worth 10.9%, and Teleflex turns slightly negative. Becton's own 28 July gain followed a fresh Buy initiation from UBS with a $190 target, not a business event. Overhanging all four: the Section 232 investigation into medical equipment imports remains unresolved, with annual tariff exposure for the largest device makers running from $200m to over $450m.

The setup

Where it stands — Four suppliers of hospital consumables re-rated with their whole sector in a month; only Merit Medical's growth kept pace with its multiple.

Would confirm — Merit holding organic constant-currency growth at or above 6.9% in the third quarter, its raised guidance floor.

Would invalidate — Teleflex missing the lowered 3.5–4.5% growth range, or Becton guiding fiscal 2027 below low-single-digit revenue growth.

Watch next — Becton's fiscal fourth-quarter report in early November, its first with full-year 2027 guidance; Merit and ICU Medical report late October.

Valuation — Forward earnings: Becton 14.5x, Merit 21.1x, Teleflex 20.6x, ICU Medical 22.4x, against 11.5x, 14.5x and 15.1x three months ago.